Cancer Advisor

Executive Summary Cancer immunotherapy represents one of the most consequential paradigm shifts in oncology since the advent of combination chemotherapy [1–3]. By targeting immune checkpoints, tumor antigens, or immune effector cells themselves, immunotherapies have delivered durable, and in some cases curative, responses in a subset of patients across historically lethal malignancies [4–7]. However, population-level benefit remains heterogeneous. Immune checkpoint inhibitors (ICIs) consistently extend survival in several cancers, although absolute overall survival (OS) gains are often modest at a population level . Many regulatory approvals rely on surrogate endpoints rather than mature overall survival (OS) data [32,35], immune-related toxicities can be severe or permanent [28–30], and costs place substantial strain on healthcare systems [38–40]. Real-world effectiveness frequently diverges from pivotal trial results [54]. Credit:  Statista 1. Introduction 1.1 Historical Context...

Authors:  Ilyes Baghli 1 , William Makis 2 , Paul E. Marik 3 , Michael J. Gonzalez 4,5,6 , William B. Grant 7 , Ron Hunninghake 8 , Thomas E. Levy 8 , Homer Lim 9 , Richard Z. Cheng 10 , Igor Bondarenko 11 , Paul Bousquet 12 , Roberto Ortiz 13 , Mignonne Mary 14 , Dominic P. D’Agostino 15 , Pierrick Martinez 16 1  International Society for Orthomolecular Medicine, Toronto, ON, Canada 2  Alberta Health Services, Cross Cancer Institute, Edmonton, AB, Canada 3  Frontline COVID-19 Critical Care Alliance, Washington, DC, USA 4  University of Puerto Rico, Medical Sciences Campus, School of Public Health, San Juan, PR 5  Universidad Central del Caribe, School of Chiropractic, Bayamon, Puerto Rico 6  EDP University, Naturopathic Sciences Program, Hato Rey, Puerto Rico 7  Sunlight, Nutrition, and Health Research Center, San Francisco, CA, USA 8  Riordan Clinic, 3100 North Hillside, Wichita, KS, USA 9  Akesis Holistic Health, Manila, Philippines 1...

Abstract Background : Stage 4 prostate cancer remains largely incurable, and new strategies are urgently needed. Preclinical evidence suggests antiparasitic agents such as ivermectin and mebendazole, when combined with anti-inflammatory supplements and lifestyle changes, may offer survival benefits. Objective : To simulate the long-term efficacy and safety of a combined therapeutic protocol including high-dose ivermectin, mebendazole, nutritional supplements, and structured lifestyle changes in patients with stage 4 prostate cancer. Methods : A double-blind, randomized, placebo-controlled simulation trial was designed with 10,000 patients per arm over a 10-year follow-up. The intervention arm received high-dose ivermectin (1 mg/kg, 5x/week), mebendazole (500 mg BID), supplements (vitamin D, curcumin, omega-3, EGCG, berberine), and a structured diet/lifestyle protocol. The control arm received standard of care plus placebo. Survival outcomes and adverse event rates were simulated usi...

What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...